Brief: Isofol Says Agent Study Confirms Topline Results
Nov 25 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST :
* FINAL DATA FROM THE AGENT STUDY CONFIRMS TOPLINE RESULTS
* ANALYSIS OF AGENT STUDY'S FINAL DATA CONFIRMED TOPLINE
RESULTS
PRESENTED ON AUGUST 3, 2022
* ISOFOL IS IN PARALLEL CONTINUING TO INVESTIGATE POSSIBLE
FUTURE
PATHS FORWARD FOR COMPANY
Source text for Eikon: ID:nWkr6Rp05z
Further company coverage: ISOFOL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million
Brief: Isofol Medical Announces Bfarm Approval Of Optimized Phase Ib/Ii Study Design
Brief: Isofol Gets Gross Proceeds Of SEK 18.9 Mln In Connection With Exercise Of Warrants And Guarantee Commitments
Brief: Isofol Secures License Rights For Arfolitixorin In Autism